StockMirror — Stock Screener

MEDPLUS Q3 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

MedPlus reported a strong Q3 FY26 with revenue of INR 18,061M, driven by 10%+ SSSG, 182 net new stores, and robust diagnostics growth. Margins were stable despite a one-time labor code charge. Key positives include successful incentive restructuring, strong private label non-pharma growth, working capital improvement, and confidence in the margin expansion path. The call conveyed operational execution strength and a clear strategy focused on private label mix and store-level productivity.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management is driving store expansion (growth) while simultaneously focusing on private label mix, especially high-margin non-pharma, and operational efficiencies to improve profitability.

About MedPlus Health Services Limited

MedPlus Health Services Limited (MEDPLUS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More